Literature DB >> 14727984

Antihypertensive drugs: an overview.

C Venkata S Ram1.   

Abstract

For most patients with systemic hypertension, long-term drug treatment is indicated and is beneficial. There is overwhelming evidence to suggest that antihypertensive drugs offer protection against complications of hypertension. Whereas nondrug therapeutic options should be implemented in all patients, a vast majority will require pharmacological treatment to achieve goal blood pressure levels. Fortunately, a number of drugs are available to accomplish successful treatment of hypertensive disorders. While it is conventional to initiate treatment with a single drug, a suitable combination of drugs is often required to control the blood pressure effectively. Although diuretics and beta-blockers are effective and well tolerated, other classes of drugs are being increasingly used as the initial choice of therapy for hypertension. Every class of antihypertensive drugs offer advantages and some disadvantage; the physician should weigh the benefits and risks in selecting one drug over another. While the clinical parameters are followed in the management of patients with hypertension, it is also necessary to monitor the patients' biochemical profile periodically in order to modify and adjust the therapy accordingly. A careful selection of drug therapy along with close follow-up offers the best prospect to reduce the burden of morbidity and mortality in hypertension. This article provides an overview of drugs in the management of patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14727984     DOI: 10.2165/00129784-200202020-00002

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  12 in total

Review 1.  Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.

Authors:  Pedro Marques da Silva
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study.

Authors:  Steven G Chrysant
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 3.  Desirable therapeutic characteristics of an optimal antihypertensive agent.

Authors:  Lisa Mustone Alexander
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.

Authors:  Richard B R Muijsers; Monique P Curran; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Using fixed-dose combination therapies to achieve blood pressure goals.

Authors:  Steven G Chrysant
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 6.  Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension.

Authors:  David H G Smith
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Current perspectives on the use of meditation to reduce blood pressure.

Authors:  Carly M Goldstein; Richard Josephson; Susan Xie; Joel W Hughes
Journal:  Int J Hypertens       Date:  2012-03-05       Impact factor: 2.420

8.  Antihypertensive treatments and risks of lung Cancer: a large population-based cohort study in Hong Kong.

Authors:  Jinhui Li; Amy S M Lam; Sarah T Y Yau; Karen K L Yiu; Kelvin K F Tsoi
Journal:  BMC Cancer       Date:  2021-11-11       Impact factor: 4.430

Review 9.  Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment.

Authors:  Hui-Qing Chen; Jin-Yu Gong; Kai Xing; Mou-Ze Liu; Huan Ren; Jian-Quan Luo
Journal:  Front Med (Lausanne)       Date:  2022-01-19

Review 10.  Mindfulness interventions reduce blood pressure in patients with non-communicable diseases: A systematic review and meta-analysis.

Authors:  Ungsinun Intarakamhang; Ann Macaskill; Pitchada Prasittichok
Journal:  Heliyon       Date:  2020-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.